Impact of Body Mass Index Categories on Outcomes in Patients with DLBCLOverweight status linked to better survival in certain lymphoma

Frontiers in Medicine Published June 24, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Overweight status correlates with better survival in DLBCL, while underweight status is associated with poorer outcomes.

This systematic review and meta-analysis evaluated the prognostic impact of body mass index (BMI) on patients diagnosed with Diffuse Large B-cell Lymphoma (DLBCL). By analyzing 23 studies, researchers compared various BMI categories against a normal-weight reference group to determine effects on survival metrics.

Findings indicate that overweight status is significantly associated with both improved overall survival and better progression-free survival. Specifically, patients in the overweight category demonstrated lower hazard ratios for mortality and disease progression compared to their normal-weight counterparts. These results suggest a potentially favorable prognostic association for patients with higher BMI indices.

Conversely, underweight status was linked to inferior outcomes. Patients categorized as underweight showed significantly poorer overall survival and progression-free survival. While obesity was analyzed, the data did not show a statistically significant correlation with survival outcomes compared to normal weight.

Clinicians should note that these findings are based on observational data and indicate associations rather than direct causality. While overweight status may suggest a more favorable prognosis in this specific cohort, current evidence is insufficient to confirm a definitive prognostic impact for obesity.

How this fits prior evidence

This meta-analysis addresses a gap in understanding how patient physical characteristics like BMI influence outcomes in diffuse large B-cell lymphoma. While previous coverage noted that Zanubrutinib shows high response rates and durable survival benefits across various DLBCL groups, this study specifically explores the impact of BMI categories. It confirms that overweight status is associated with better OS (HR = 0.82) and PFS (HR = 0.83), while underweight status correlates with poorer outcomes.

When facing a diagnosis like diffuse large B-cell lymphoma, every detail about a patient's physical health matters. A large review of 23 studies looked at how body mass index (BMI) relates to survival and disease progression for patients undergoing R-CHOP treatment.

The data showed a clear difference based on weight categories. Patients classified as overweight had better overall survival and stayed free from progressing disease longer than those with normal weights. In contrast, being underweight was linked to poorer survival outcomes and faster disease progression.

It is important to note that while the study found a link for overweight patients, it did not find a significant difference for those classified as obese. Because these results come from observational data, we cannot say weight causes these outcomes, only that they are linked. Talk to your doctor about how your specific health profile impacts your treatment plan.

What this means for you:

Overweight status is linked to better survival in some lymphoma patients, while being underweight may signal a poorer outlook.

Common questions

How does weight affect the outlook for lymphoma patients?

Patients with diffuse large B-cell lymphoma who are overweight showed better overall survival and progression-free survival compared to normal-weight patients. However, being underweight was associated with inferior outcomes in both categories.

Does being obese change the outlook for these patients?

The study did not find a significant association between obesity and overall survival or progression-free survival. The evidence is currently insufficient to confirm if obesity has a specific impact on prognosis.

Is this finding a guarantee of better results for overweight patients?

No, these results are based on observational data, which shows an association rather than a direct cause. You should speak with your doctor to understand how these findings apply to your specific case.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

BackgroundThe prognostic significance of body mass index (BMI) in diffuse large B-cell lymphoma (DLBCL) remains uncertain. We conducted a systematic review and meta-analysis to evaluate the associations between BMI and overall survival (OS) and progression-free survival (PFS) in patients with DLBCL.MethodsA systematic search of the Cochrane Library, PubMed, and Embase was conducted up to April 14, 2026, with additional reference screening. Random-effects models were used to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs).ResultsOf 764 records identified, 23 studies were included. In the main analyses, overweight status, defined according to study-specific thresholds, including Asian-specific cutoffs where applicable, was associated with better OS (HR = 0.82, 95% CI: 0.73–0.92, P = 0.001) and PFS (HR = 0.83, 95% CI: 0.72–0.96, P = 0.011). These associations remained consistent in subgroup analyses restricted to studies using R-CHOP-like regimens, multivariable-adjusted estimates, and normal-weight patients as the reference group. In BMI category-specific analyses, underweight status was associated with inferior OS (HR = 1.85, 95% CI: 1.30–2.64, P = 0.001) and PFS (HR = 1.64, 95% CI: 1.11–2.42, P = 0.013). By contrast, overweight status was associated with better OS (HR = 0.77, 95% CI: 0.70–0.84, P < 0.001) and PFS (HR = 0.80, 95% CI: 0.69–0.93, P = 0.004). Obesity was not significantly associated with either OS (HR = 0.93, 95% CI: 0.75–1.15, P = 0.508) or PFS (HR = 0.95, 95% CI: 0.80–1.13, P = 0.541).ConclusionAvailable evidence suggests that overweight status may be associated with better survival outcomes in DLBCL, whereas underweight status may be associated with poorer prognosis. Current evidence remains insufficient to confirm a significant prognostic impact of obesity.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42024607212.

Impact of Body Mass Index Categories on Outcomes in Patients with DLBCLOverweight status linked to better survival in certain lymphoma

How this fits prior evidence

Common questions

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Impact of Body Mass Index Categories on Outcomes in Patients with DLBCLOverweight status linked to better survival in certain lymphoma

How this fits prior evidence

Common questions

More on Diffuse Large B-Cell Lymphoma

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Related in Nutrition & Obesity Medicine

From Other Specialties